Henlius Gets Fourth Chinese Biosimilar With Bevacizumab Nod

Cites ‘Huge Demand’ For Avastin Rival In China; Also Developing Ophthalmic Version

 
• By Dave Wallace

Shanghai Henlius Biotech has celebrated its fourth Chinese biosimilar approval with the NMPA’s endorsement of its bevacizumab biosimilar. The company is also working on an ophthalmic version to treat wAMD.

Four Thumbs Up Icons Yellow
The NMPA nod marks Henlius’ fourth Chinese biosimilar approval • Source: Alamy

More from Biosimilars

More from Products